Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property

Journal of Immunology

Volumn 183, Issue 12, 2009, Pages 8176-8185

  Kishuku, Masatoshi ^a   Nishioka, Yasuhiko ^a   Abe, Shinji ^a   Kishi, Jun ^a   Ogino, Hirokazu ^a   Aono, Yoshinori ^a   Azuma, Momoyo ^a   Kinoshita, Katsuhiro ^a   Rentsenhand, Batmungh ^a   Makino, Hideki ^a   Ranjan, Priya ^a   Minakuchi, Kazuo ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; FLT1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SCID MOUSE; SUPERNATANT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; COMPARATIVE STUDY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SECRETION; TRANSPLANTATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, SCID; MONOCYTES; NEOPLASM TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 76249091676     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803849     Document Type: Article

References (36)

1. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
2. Ferrara, N., and R. S. Kerbel. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
3. Noonan, D. M., A. De Lerma Barbaro, N. Vannini, L. Mortara, and A. Albini. 2008. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27: 31-40.
4. Strasly, M., F. Cavallo, M. Geuna, S. Mitola, M. P. Colombo, G. Forni, and F. Bussolino. 2001. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166: 3890-3899. (Pubitemid 32224915)
5. McLean, K., and R. J. Buckanovich. 2008. Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl. Res. 151: 59-67.
6. Murdoch, C., M. Muthana, S. B. Coffelt, and C. E. Lewis. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8: 618-631.
7. Sunderkötter, C., K. Steinbrink, M. Goebeler, R. Bhardwaj, and C. Sorg. 1994. Macrophages and angiogenesis. J. Leukocyte Biol. 55: 410-422.
8. Mantovani, A., T. Schioppa, C. Porta, P. Allavena, and A. Sica. 2006. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25: 315-322. (Pubitemid 44922352)
9. Sica, A., T. Schioppa, A. Mantovani, and P. Allavena. 2006. Tumour- associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42: 717-727.
10. Coukos, G., F. Benencia, R. J. Buckanovich, and J. R. Conejo-Garcia. 2005. The role of dendritic cell precursors in tumour vasculogenesis. Br. J. Cancer 92: 1182-1187. (Pubitemid 40604389)
11. Sozzani, S., M. Rusnati, E. Riboldi, S. Mitola, and M. Presta. 2007. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol. 28: 385-392. (Pubitemid 47385377)
12. Riboldi, E., T. Musso, E. Moroni, C. Urbinati, S. Bernasconi, M. Rusnati, L. Adorini, M. Presta, and S. Sozzani. 2005. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J. Immunol. 175: 2788-2792. (Pubitemid 41170494)
13. Curiel, T. J., P. Cheng, P. Mottram, X. Alvarez, L. Moons, M. Evdemon-Hogan, S. Wei, L. Zou, I. Kryczek, G. Hoyle, et al. 2004. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64: 5535-5538.
14. Roskoski, R., Jr. 2007. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 62: 179-213. (Pubitemid 46679285)
15. Shibuya, M., S. Yamaguchi, A. Yamane, T. Ikeda, A. Tojo, H. Matsushime, and M. Sato. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524.
16. de Vries, C., J. A. Escobedo, H. Ueno, K. Houck, N. Ferrara, and L. T. Williams. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
17. Terman, B. I., M. Dougher-Vermazen, M. E. Carrion, D. Dimitrov, D. C. Armellino, D. Gospodarowicz, and P. Böhlen. 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187: 1579-1586.
18. Millauer, B., S. Wizigmann-Voos, H. Schnürch, R. Martinez, N. P. Møller, W. Risau, and A. Ullrich. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846.
19. Shibuya, M. 2006. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39: 469-478.
20. Kendall, R. L., and K. A. Thomas. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90: 10705-10709.
21. Kendall, R. L., G. Wang, and K. A. Thomas. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226: 324-328.
22. Roeckl, W., D. Hecht, H. Sztajer, J. Waltenberger, A. Yayon, and H. A. Weich. 1998. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell Res. 241: 161-170.
23. + blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur. J. Immunol. 31: 2633-2641.
24. Nishioka, Y., M. Hirao, P. D. Robbins, M. T. Lotze, and H. Tahara. 1999. Induction of systemic and therapeutic antitumor immunity using injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59: 4035-4041.
25. Mitani, K., Y. Nishioka, K. Yamabe, H. Ogawa, T. Miki, H. Yanagawa, and S. Sone. 2003. Soluble Fas in malignant pleural effusion and its expression in lung cancer cells. Cancer Sci. 94: 302-307.
26. Nishimura, N., Y. Nishioka, T. Shinohara, and S. Sone. 2001. Enhanced efficiency by centrifugal manipulation of adenovirus- mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum. Gene Ther. 12: 333-346. (Pubitemid 32186646)
27. Tomimoto, H., S. Yano, H. Muguruma, S. Kakiuchi, and S. Sone. 2007. Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusion. J. Med. Invest. 54: 146-153.
28. Eubank, T. D., R. Roberts, M. Galloway, Y. Wang, D. E. Cohn, and C. B. Marsh. 2004. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 21: 831-842.
29. Nishioka, Y., S. Yano, F. Fujiki, N. Mukaida, K. Matsushima, T. Tsuruo, and S. Sone. 1997. Combined therapy of multidrug- resistant human lung cancer with anti-p-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int. J. Cancer 71: 170-177.
30. Li, Q., S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, and S. Sone. 2007. The therapeutic efficacy of anti-vascular endothelial growth factor antibody: bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin. Cancer Res. 13: 5918-5925.
31. Barleon, B., P. Reusch, F. Totzke, C. Herzog, C. Keck, G. Martiny-Baron, and D. Marmé. 2001. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4: 143-154.
32. Oyama, T., S. Ran, T. Ishida, S. Nadaf, L. Kerr, D. P. Carbone, and D. I. Gabrilovich. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160: 1224-1232.
33. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2: 1096-1103.
34. Saito, H., S. Tsujitani, M. Ikeguchi, M. Maeta, and N. Kaibara. 1998. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78: 1573-1577.
35. Inoshima, N., Y. Nakanishi, T. Minami, M. Izumi, K. Takayama, I. Yoshino, and N. Hara. 2002. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin. Cancer Res. 8: 3480-3486.
36. Iwamoto, M., H. Shinohara, A. Miyamoto, M. Okuzawa, H. Mabuchi, T. Nohara, G. Gon, M. Toyoda, and N. Tanigawa. 2002. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104: 92-97.